Cardio-vascular diseases

Cardio-vascular diseases

Cardio-vascular diseases represent a worldwide public health concern


Cardio-vascular diseases are the leading cause of death in the world, ahead of cancer. They were responsible for 17 million deaths in 2008 and are expected to cause more than 24 million deaths in 2030. This figure is highly correlated with the increase in aging (World Health Organization).

The current global market for cardio-vascular in vitro diagnostics is growing at fast pace (USD 5.0°bn in 2016 with a CAGR of +8%). The “emergency room” sub-segment of this market is estimated to reach USD2°bn in 2016 (IVS Market Reports).

Considerable direct and indirect costs are associated with these diseases (€192 bn in Europe; $450 bn in US in 2008). Emergency rooms are expensive and saturated. They are both capital and labor intensive; Delayed diagnostics due to the use of machines and long processes postpone the initiation of treatment. This increases the likelihood of patient's' long term disabilities and the costs of their care and medication expenses, etc


The lack of robust, rapid and quantitative portable diagnostics leads to mortality and patients disabilities and generates various costs for insurers and health care providers. As a result, physicians and healthcare providers are in dire need of cost and time efficiency.